VRCA Stock Analysis: Buy, Sell, or Hold?
VRCA - Verrica Pharmaceuticals Inc. Common Stock
$6.95
-0.42 (-5.70%)
▼
5d:
-15.66%
30d:
+17.6%
90d:
+25.0%
WAIT
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Get Alerted When VRCA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: VRCA is down 15.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: VRCA is down 15.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: VRCA is currently trading at $6.95, which is considered fair relative to its 30-day fair value range of $5.80 to $7.35.
Technical Outlook: Technically, VRCA is in a downtrend. Immediate support is located at $6.15, while resistance sits at $8.50. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: VRCA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $16.50 (+137.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VRCA is in a downtrend. Immediate support is located at $6.15, while resistance sits at $8.50. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: VRCA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $16.50 (+137.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$5.80 -
$7.35
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
81.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.7%)
- BULLISH: Trading 137.4% below Wall St target ($16.50)
- WARNING: Recommendation downgraded due to -15.7% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$5.80 -
$7.35
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$6.15
Resistance Level
$8.50
Current Trend
Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.08
Wall Street Target
$16.50
(+137.4%)
Revenue Growth (YoY)
1380.2%
Profit Margin
-50.3%
Share & Embed Analysis
Last updated: May 14, 2026 8:29 PM ET
Data refreshes hourly during market hours. Next update: 9:29 PM
Data refreshes hourly during market hours. Next update: 9:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VRCA showing a specific setup today?
Insider Activity (6 Months)
6
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
David Zawitz
BUY
10000 shares
2025-11-25
Jayson Rieger
BUY
94311 shares
2025-11-25
John J Kirby
BUY
3536 shares
2025-11-25
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 60 BUY |
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 50 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 59 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 65 BUY |
